- Home
- HCA vs GSK Comparison
HCA vs GSK Comparison
Compare HCA & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCA
- GSK
- Stock Information
- Founded
- HCA 1968
- GSK 1715
- Country
- HCA United States
- GSK United Kingdom
- Employees
- HCA N/A
- GSK N/A
- Industry
- HCA Hospital/Nursing Management
- GSK Biotechnology: Pharmaceutical Preparations
- Sector
- HCA Health Care
- GSK Health Care
- Exchange
- HCA Nasdaq
- GSK Nasdaq
- Market Cap
- HCA 90.9B
- GSK 81.9B
- IPO Year
- HCA N/A
- GSK N/A
- Fundamental
- Price
- HCA $436.47
- GSK $43.45
- Analyst Decision
- HCA Buy
- GSK Hold
- Analyst Count
- HCA 17
- GSK 2
- Target Price
- HCA $411.43
- GSK N/A
- AVG Volume (30 Days)
- HCA 1.3M
- GSK 5.7M
- Earning Date
- HCA 10-24-2025
- GSK 10-29-2025
- Dividend Yield
- HCA 0.66%
- GSK 3.72%
- EPS Growth
- HCA 11.48
- GSK N/A
- EPS
- HCA 23.73
- GSK 1.13
- Revenue
- HCA $72,698,000,000.00
- GSK $43,336,073,439.00
- Revenue This Year
- HCA $7.33
- GSK $5.43
- Revenue Next Year
- HCA $4.37
- GSK $5.14
- P/E Ratio
- HCA $18.44
- GSK $38.43
- Revenue Growth
- HCA 6.37
- GSK 0.59
- 52 Week Low
- HCA $289.98
- GSK $31.72
- 52 Week High
- HCA $439.01
- GSK $45.59
- Technical
- Relative Strength Index (RSI)
- HCA 75.04
- GSK 61.93
- Support Level
- HCA $425.71
- GSK $43.04
- Resistance Level
- HCA $429.44
- GSK $45.59
- Average True Range (ATR)
- HCA 8.37
- GSK 0.81
- MACD
- HCA 1.71
- GSK 0.25
- Stochastic Oscillator
- HCA 94.46
- GSK 66.27
About HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.